Lung Cancer, Nonsmall Cell

Oncology
4
Pipeline Programs
5
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
150%
Small Molecule
150%
+ 3 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
CrizotinibPhase 2Small Molecule1 trial
Active Trials
NCT03088930Completed3Est. Jan 2021
Biotest Pharmaceuticals
Biotest PharmaceuticalsGermany - Dreieich
1 program
1
NanoPacPhase 21 trial
Active Trials
NCT04314895CompletedEst. Sep 2023
Genentech
GenentechCA - Oceanside
1 program
1
AtezolizumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT04691817Recruiting28Est. Sep 2027
Bristol Myers Squibb
1 program
1
Blood screeningPhase 1/21 trial
Active Trials
NCT04631731Unknown200Est. Dec 2025
Verona Pharma
Verona PharmaUK - London
1 program
ImmunonutritionN/A1 trial
Active Trials
NCT05384873RecruitingEst. Jul 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Biotest PharmaceuticalsNanoPac
PfizerCrizotinib
GenentechAtezolizumab
Bristol Myers SquibbBlood screening
Verona PharmaImmunonutrition

Clinical Trials (5)

Total enrollment: 231 patients across 5 trials

NCT04314895Biotest PharmaceuticalsNanoPac

Trial of NanoPac Intratumoral Injection in Lung Cancer

Start: Apr 2021Est. completion: Sep 2023
Phase 2Completed
NCT03088930PfizerCrizotinib

Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

Start: Dec 2017Est. completion: Jan 20213 patients
Phase 2Completed
NCT04691817GenentechAtezolizumab

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Start: Jul 2023Est. completion: Sep 202728 patients
Phase 1/2Recruiting
NCT04631731Bristol Myers SquibbBlood screening

Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity

Start: Dec 2020Est. completion: Dec 2025200 patients
Phase 1/2Unknown
NCT05384873Verona PharmaImmunonutrition

Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer

Start: Jun 2023Est. completion: Jul 2027
N/ARecruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 231 patients
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)